| Price | $0.48 |
| Year Range | $0.33 – $5.73 |
| Market Cap | $6.1M |
| Industry | Biotechnology |
What Is Reviva Pharmaceuticals’s AI Stock Analysis?
Reviva Pharmaceuticals’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Reviva Pharmaceuticals’s momentum in near-real time.
Reviva Pharmaceuticals (RVPH) has an AltIndex AI Score of 45/100, currently a Hold signal. The AI Score distills Reviva Pharmaceuticals's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Reviva Pharmaceuticals’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Reviva Pharmaceuticals — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving RVPH’s AI Score?
Fundamentals
Net income for the last quarter was $-2,448B. This represents a decrease of 76,590,668.36% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 40,435,788.67%, which may be a cause for concern. Ebitda for the last quarter was $-2,618B. This represents a decrease of 81,986,662.68% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 43,330,542.21%, which may be a cause for concern.
See Reviva Pharmaceuticals’s earnings and insider transactions.
Technicals
Today's stock price is $0.48. This is equal to the stock price a month ago, showing short-term stability. However, compared to a year ago, there is a decrease of 95.91%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $0.50, which is lower than the previous SMA10 of $0.50. This suggests a potential downward trend in price movement. The RSI is 51.7, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
Reviva Pharmaceuticals has an estimate of 6,000 visitors to their webpage. The number of visitors is down by -33% in the last couple of months, a worrisome trend as this can indicate a loss in customers.
Explore Reviva Pharmaceuticals’s job postings, web traffic and app downloads.
Sentiment & social
Reviva Pharmaceuticals has 490 followers on their Twitter page. The number of followers is down by -1% in the last couple of months, indicating a loss in interest in the company.
Track Reviva Pharmaceuticals’s market sentiment.
Frequently Asked Questions: Reviva Pharmaceuticals AI Stock Analysis
Reviva Pharmaceuticals's AltIndex AI Score is 45/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Reviva Pharmaceuticals a Hold (45/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Reviva Pharmaceuticals — company overview, fundamentals, technicals and alternative data, with a recommendation. See the RVPH AI Score or sign up to read the full thesis.
